Locations:
Search IconSearch
November 24, 2020/Cancer

Small-Incision Guarded Hydroaspiration in Patient with Small Iris Lesion

35-year-old presents with suspected iris melanoma

Arun Singh, MD

A 35-year-old presented at Cole Eye Institute with a lesion in the left iris. He had been seen annually by an outside optometrist for seven years. The lesion had not been noted previously.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The patient did not have any visual symptoms, and his visual acuity was 20/20 in both eyes.

The elevated pigmented lesion in the iris was associated with nodularity along the pupillary margin between the 10- and 11-o’clock position. There were no feeder vessels or neovascularization of the iris on exam.

OCT

Anterior segment OCT showed multinodular iris thickening.

Lesion

Although the lesion was small and appeared like a nevus, melanoma was suspected due to recent onset.

“Freckles and nevi of the iris are very common,” says Arun D. Singh, MD, Director of Ophthalmic Oncology at Cole Eye Institute. “All spots aren’t malignant, but there are some clues that can indicate which spots likely are.”

According to Dr. Singh, iris lesions suspicious for melanoma are those that:

  • Are newly detected or recently changed.
  • Distort the iris more than 3 mm in any dimension. “If it’s simply sitting on the iris, like a paint spot, we’re more apt to think it’s benign,” says Dr. Singh.
  • Contain blood vessels.
  • Have nodular elevations.

Excisional biopsy with pupilloplasty

Following discussion of treatment options, the patient agreed to undergo excisional biopsy of the lesion with pupilloplasty using a small-incision approach.

Conventionally, iris resection for a suspected malignancy has involved a large incision in the cornea and sclera and the removal of 25% or more of the iris. This sector iridectomy has been associated with increased risk of wound-related complications, tumor seeding and recurrence, and photophobia due to iris defect.

Almost 15 years ago, Dr. Singh developed a new technique: small-incision guarded hydroaspiration (SINGH procedure). Instead of one large incision, there are multiple small incisions. After excising the tumor, plastic tubing containing a sodium hyaluronate solution is inserted into the anterior chamber. Using a syringe, the excised lesion is pulled into the tube, where it is isolated and removed safely as the tube is withdrawn from the anterior chamber. This prevents the tumor from being pulled across the wound, possibly shedding cells and seeding the edges of the wound.

Advertisement

The next step, pupilloplasty, restores the iris to a near-normal shape with a suturing slip-knot technique since the iris does not have capacity to heal. This restoration of the iris not only repairs the cosmetic defect but helps prevent photophobia.

“Healing was much slower — six weeks or longer — with conventional techniques using the larger incision,” says Dr. Singh. “Distortion of the cornea was a problem too. If you’d make a 6 mm wound in the cornea, it would be irregular when it healed. Multiple smaller incisions allow faster healing. Patients typically have normal vision within a week or so.”

In this case, as clinically suspected, histopathology confirmed iris melanoma. All surgical margins were negative.

One day later, the patient’s vision was 20/30 with minimal postoperative inflammation.

Post-surgery

Four weeks following surgery, the patient’s vision was normal (20/20) without change in corneal astigmatism. The pupil size was equal between the two eyes in ambient light.

Patient eye

Now three years since surgery, the patient remains recurrence-free.

Three years postop

Better risk-benefit ratio than conventional iridectomy

Melanoma of the uvea is rare, occurring in just six per 1 million people. Approximately 10% of uveal melanoma occurs in the iris — extremely rare.

Two decades ago, the only option for removing uveal melanoma was an iridectomy with a large corneoscleral incision, requiring six weeks or more of healing and slow visual recovery. New techniques and better instrumentation now provide another option, with a better risk-benefit ratio, says Dr. Singh.

“Today, if I see a lesion growing, I recommend we remove it because I know we can do so safely with minimally invasive techniques,” he says. “In the past, we would just watch the lesion and hope to avoid a big surgery.”

Advertisement

Even small lesions can be suspicious for melanoma, which can be removed easily with low risk to the patient, he concludes.

Advertisement

Related Articles

Dr. Mukhejee and colleagues
January 22, 2026/Cancer/News & Insight
Rare Cancers and Blood Disease Program Accelerates Diagnostic Journey

Multidisciplinary teams bring pathological and clinical expertise

genetic test
January 16, 2026/Cancer/News & Insight
Five Percent of U.S. Population Carries Pathogenic Variants Associated with Cancer Risk

Genetic variants exist irrespective of family history or other contributing factors

GLP-1
January 12, 2026/Cancer/Blood Cancers
GLP-1a Therapy Improves Survival in Patients with Polycythemia Vera and Myelodysplastic Syndromes

Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists

Oncology nurse
January 9, 2026/Cancer
Improving Patient Experience in Inpatient Hematology: A Nursing Perspective

Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Ad